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Abstract
Background: Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs
the progression of chronic kidney disease (CKD). The aldosterone antagonist spironolactone has an antiproteinuric effect,
but its use is limited by side effects. The present study evaluated the short-term antiproteinuric effect and safety of the
selective aldosterone antagonist eplerenone in non-diabetic CKD.
Study Design: Open randomized cross-over trial.
Setting and Participants: Forty patients with non-diabetic CKD and urinary albumin excretion greater than 300 mg/
24 hours.
Intervention: Eight weeks of once-daily administration of add-on 25–50 mg eplerenone to stable standard antihypertensive
treatment including RAS-blockade.
Outcomes & Measurements: 24 hour urinary albumin excretion, BP, p-potassium, and creatinine clearance.
Results: The mean urinary albumin excretion was 22% [CI: 14,28], P,0.001, lower during treatment with eplerenone. Mean
systolic BP was 4 mmHg [CI: 2,6], P=0.002, diastolic BP was 2 mmHg [CI: 0,4], P=0.02, creatinine clearance was 5% [CI: 2,8],
P=0.005, lower during eplerenone treatment. After correction for BP and creatinine clearance differences between the
study periods, the mean urinary albumin excretion was 14% [CI: 4,24], P=0.008 lower during treatment. Mean p-potassium
was 0.1 mEq/L [CI: 0.1,0.2] higher during eplerenone treatment, P,0.001. Eplerenone was thus well tolerated and no
patients were withdrawn due to hyperkalaemia.
Limitations: Open label, no wash-out period and a moderate sample size.
Conclusions: In non-diabetic CKD patients, the addition of eplerenone to standard antihypertensive treatment including
RAS-blockade caused a moderate BP independent fall in albuminuria, a minor fall in creatinine clearance and a 0.1 mEq/L
increase in p-potassium.
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Introduction
Reductions in blood pressure (BP) and urinary albumin
excretion in chronic kidney disease (CKD) have been shown to
reduce the risk of cardiovascular (CV) events and improve renal
outcome. A reduction in proteinuria is considered a surrogate
marker of reduction in CKD progression rate and residual
proteinuria has influence on the course of progression to end stage
renal disease [1–5].
Inhibition of the renin-angiotensin system (RAS) attenuates the
progression of diabetic and non-diabetic CKD in patients with
proteinuria and hypertension in excess of the BP lowering effect
alone [6,7]. There is increasing evidence that aldosterone has
effects on the vascular wall leading to fibrosis, glomerular sclerosis
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26904and arterial stiffness, factors which in themselves lead to worsening
of proteinuria and progression of CKD [8–10]. Inhibition of
aldosterone by the non-selective antagonist spironolactone has
been shown to reduce albuminuria in both diabetic and non-
diabetic CKD [11–15]. The antiproteinuric effect of the selective
aldosterone inhibitor, eplerenone, has previously been studied in
type 2 diabetic patients with microalbuminuria [16] and in
essential hypertension [17]. The aim of the present study was to
evaluate the short-term effects of eplerenone in patients with non-
diabetic CKD.
Methods
Ethics Statement
All patients were included after written informed consent. The
study was approved by The Ethical Committee of Copenhagen
County and the Danish Medicines Agency. The study was carried
out according to the Helsinki Declaration.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Design
The study was carried out in a randomized, open-label, cross-
over design comparing an 8-week control period with an 8-week
period of once-daily administration of eplerenone. Randomization
was done by the principal investigator drawing sealed opaque
envelopes. Patients were either allocated to start in the
intervention period followed by the control period or vice versa
with no wash-out period in between.
Study Participants
Inclusion criteria were: age .18 years, persistent 24 hour
proteinuria, initially planned as .2000 mg, but after inclusion of
the first patient changed to .500 mg or albuminuria .300 mg,
BP.130/80 mmHg or ongoing stable antihypertensive treatment,
including RAS-blockade. There was no demand for ongoing RAS-
blocking therapy.
Exclusion criteria were: diabetic nephropathy, creatinine clear-
ance ,20 mL/min, plasma (p-) potassium .5.0 mEq/l, allergy to
aldosterone antagonists, chronic liver insufficiency, ongoing treat-
mentwithCYP3A4-inhibitors,lithiumorimmunosuppressiveagents
including steroids, invalidating psychiatric disorders, other severe
non-renal disease, woman of childbearing potential not using safe
contraception, pregnancy or breast-feeding. Patients were recruited
from and followed in the outpatient clinics of the two participating
departments. All patients were seen by the principal investigator.
Study protocol
Eplerenone treatment was initiated by a once daily oral dose of
25 mg administered as add-on treatment to ongoing therapy. The
dose was doubled after one week to 50 mg once daily for seven
weeks. Patients were seen at weeks 0, 1, 2, 4, 8, 9, 10, 12 and 16.
The BP goal was ,130/80 mmHg. In case of symptomatic
hypotension, reductions were primarily made in non-RAS-
blocking antihypertensive agents and in case of BP above target
non-RAS-blocking agents were added. Main outcome variables
were albuminuria based on single 24 hour urine samples collected
for every visit, fractional excretion of albumin, BP, p-potassium,
and creatinine clearance, which were measured at each visit.
Safety and withdrawal criteria
Potassium supplements were withdrawn before initiation of
eplerenone treatment. There were no dietary restrictions at trial
entry. Withdrawal criteria were any CV event, serious non-renal
disease,a persistentriseinp-creatinineabove30%ofbaselinevalue,
persistent hyperkalaemia, defined as p-potassium .5.5 mEq/L at
two successive visits, or pregnancy despite safe contraception.
Clinical and biochemical methods
BP was measured using the mercury sphygmomanometer
auscultatory method. Cuff width was selected according to arm
circumference. BP measurements were done after 5–10 minutes of
rest in the sitting position. Analysis of urinary albumin was done
by immunoturbidimetry with antibodies from Dako A/S (Konelab
PRIME 60), inter-series coefficient of variation (CV) 2% at Herlev
Hospital and Tinaquant from Roche (Roche Modular), inter-series
CV 10%, at Rigshospitalet.
P-creatinine was analyzed by the enzymatic method, MDRD-
IDMS calibrated (Vitros 5.1), inter-series CV 2% at Herlev
Hospital and by Roche Modular Enzymatic method, MDRD-
IDMS calibrated, inter-series CV 2.1% at Rigshospitalet.
Fractional albumin excretion was calculated according to the
following formula:
Ualbumin concentration   Pcreatinine concentration ðÞ = ð
Palbumin concentration   Ucreatinine concentration ðÞ Þ   100
Compliance was monitored by tablet counts at the end of
eplerenone treatment.
Statistics
A reduction of albuminuria of 25% was considered as the
minimal clinically relevant response to eplerenone treatment.
Sample size was estimated to be a total of 40 patients, (power 0.8
and level of significance 0.05). Data are presented as mean and
standard deviations (SD). Where data were not normally distribut-
ed, logarithmic transformations were made and these data are
presented as well as geometric means with 95% confidence intervals
[CI]. Changes in logarithmic transformed parameters were
calculated as ratios and additionally shown in percent.
The treatment effects were calculated by the paired samples t-
test, using the mean value of the variable over all four visits in each
period – i.e. control and treatment. Analyses of values at individual
visits were done as a secondary end-point. Before analyzing
treatment effect, analyses of carry-over and time effect were made.
To test for carry-over effect, we conducted a two-sample t-test
between the two randomization groups using the mean value of
each subject. For time effect a paired samples t-test was conducted
comparing values for each patient at the two different time
periods. Two-way ANOVA was used for testing the treatment
effect on urinary albumin excretion when adjusting for creatinine
clearance and systolic BP. One-way ANOVA was used for testing
differences in response to treatment, when level of RAS-blockade
or baseline creatinine clearance was taken into account.
Evaluation of significance over multiple periods was done by
repeated measure ANOVA. Comparisons of data from individual
visits were corrected for multiple comparisons by the Bonferroni
method. Since only baseline data were tested against data from
each of the four following visits, correction was made by
multiplying the P-values by four. When applying correction for
multiple testing the corrected P-values are shown. All P-values
were two-sided and P-values,0.05 were regarded as significant.
All confidence intervals are two-sided 95% CI. The statistical
analyses were done using the SPSS statistical software, version
17.0 and R statistical software version 2.12.1, 2011, R Foundation
for Statistical Software, Vienna, Austria.
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Forty-two patients were included in the study. One was
included by mistake fulfilling the exclusion criterion of serious
non-renal disease and was withdrawn after the first visit. Another
patient was withdrawn due to non-compliance with the urinary
collections. Thus, the statistical analysis comprises forty patients.
Two patients were withdrawn before completion, one due to
myocardial infarction (control period, study week 10) and one due
to insomnia (treatment period, study week 14). Data from these
two participants were averaged for the visits they had completed.
Thirty-eight patients completed the full study protocol; one patient
did not tolerate 50 mg eplerenone, as described below in the safety
results. All patients demonstrated very good compliance, assessed
by tablet counts. The trial was initiated in April 2007 and
completed and ended as planned in August 2009.
Baseline characteristics
Renal diagnoses were based on previous renal biopsies in
chronic glomerulonephritis (n=26), specified in table 1, and in
vascular disease (n=2). Autosomal dominant polycystic kidney
disease (n=1) was diagnosed by ultrasound scan. The remaining
patients were categorized as having chronic nephropathy of
unknown aetiology (n=12). Patients with diabetic nephropathy
were excluded.
Creatinine clearance ranged from 24 to 195 mL/min at the time
of inclusion and patients were classified as CKD stages 1 (n=18), 2
(n=10), 3 (n=10) and 4 (n=2). All patients but two were on RAS-
blockade. One patient received vitamin D supplements. Baseline
patient characteristics of all patients are presented in table 1 and 2.
The median baseline number of antihypertensive drugs in the
individual patient was two (range 0 to 5).
Urinary Albumin Excretion
Albuminuria was significantly lower during the add-on
eplerenone period as compared with the control period with a
22% [CI: 14,28], P,0.001, lower excretion, as shown in table 3.
The mean 24 hour excretion was 1481 mg [CI: 1192,1840]
during the control period and 1163 mg [CI: 921, 1468] during
add-on eplerenone. No significant carry-over, P=0.3 or time
effect, P=0.3, was detected for the urinary albumin excretion.
Reduction in albuminuria was observed in 31 of 40 patients. Mean
changes in urinary excretion of albumin over time are shown in
figure 1A, and the difference in albumin excretion during the two
periods is illustrated in figure 1B. A significant decrease was seen
after two weeks of add-on eplerenone, P=0.003. Three patients
had membranous nephropathy, a glomerular disease where
resistance to aldosterone antagonists has been reported [18]. In
two of these patients, a decreased urinary albumin excretion was
observed during add-on eplerenone, while it was unchanged in the
third patient.
Fractional albumin excretion was significantly lower in the
eplerenone period, see table 3, P,0.001.
When systolic BP reduction was taken into account, the urinary
albumin excretion was 17% [CI: 8, 25] lower during eplerenone
treatment, P,0.001. When corrected for the lower creatinine
clearance during the treatment period, the reduction in albumin
excretion was 19% [CI: 10,27], P=0.0003. When both BP and
creatinine clearance were included in the statistical model, the
total difference in 24 hour urinary albumin excretion was 14%
[CI: 4,24], P=0.008.
As there was no wash-out period between study periods,
additional analysis was done excluding the first measurements in
each block (i.e. visit 2 and 6). Excluding these measurements the
difference in urinary albumin excretion was 25% [CI: 17,32],
P,0.001. Comparing only visits 2 and 6, there was no difference
in albumin excretion between treatment and control periods, as
well as there was no detection of any significant carry-over effect,
P=0.3.
To study the influence of baseline RAS-blockade on the
antialbuminuric effect of eplerenone baseline RAS-blockade was
Table 1. Baseline clinical data.
Baseline Mean ± SD
Geometric mean [95% CI]
Gender (n)
Female/male 13/27
Age, years 45 (range, 21–71)
Ethnicity (n)
Caucasian 37
African/Asian 3
Renal Diagnosis (n)
Chronic glomerulonephritis
# 26
Vascular disease 2
ADPKD
1 1
CKD of unknown aetiology 11
Antihypertensive medication (n)
ACE-inhibitor 23
Angiotensin Receptor Blocker 8
ACE-inhibitor and Angiotensin
Receptor Blocker
7
Calcium Channel Blocker 10
Beta Blocker 6
Furosemide 14 Median 70 mg/day (range
20–250 mg)
Diuretic other 6
BMI (kg/m
2) 2764
Systolic BP (mmHg) 125613
Diastolic BP (mmHg) 86610
Note:
#IgA-nephropathy (n=11), membranous nephropathy (n=3), focal segmental
glomerulosclerosis (FSGS) (n=6), non-classified chronic glomerulonephritis
(n=6).
1ADPKD=autosomal dominant polycystic kidney disease.
doi:10.1371/journal.pone.0026904.t001
Table 2. Baseline laboratory data.
P-albumin (g/dL) 4.0060.56
P-cholesterol (mg/dL) 216.6634.8
P-creatinine (mg/dL) 1.5360.63
P-potassium (mEq/L) 4.360.4
Creatinine clearance (mL/min)* 82 [71,96]
Urine albumin excretion/24 hours (mg)* 1624 [1310, 2015]
Note: Conversion factors for units: creatinine in mg/dL to mmol/L, 688.4;
cholesterol mg/dL to mmol/L, 60.02586.
*Geometric mean and CI.
doi:10.1371/journal.pone.0026904.t002
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blockade when the daily dose of ACEi/ARB was ,J of the
maximum dose for the individual drug (n=11), moderate level
blockade when the ACEi/ARB dose was between J and K of the
maximum dose (n=18) and high level blockade when the ACEi/
ARB dose was .K the maximum dose (n=2) or in case of
combined ACEi and ARB (n=7). There was a non-significant
tendency for patients on moderate RAS-blockade to have a
greater response on eplerenone than the other groups. Patients on
combined ACEi and ARB had no significant reduction in
albuminuria during eplerenone treatment.
Blood pressure
Systolic and diastolic BP was significantly lower during add-on
eplerenone treatment when compared to the control period
(table 3). There was a significant reduction of systolic BP after two
weeks of eplerenone treatment, P=0.003. At later visits, there
were no further significant changes in systolic BP. The diastolic BP
was significantly reduced after four weeks of eplerenone treatment,
P=0.002, and there was a significant difference in diastolic BP
between the treatment period and control period at the same time
point, P=0.004.
There were no significant differences between diastolic BP at
the end of the two periods. There were no significant differences in
BP reduction between groups of low, moderate or high baseline
RAS-blockade.
There were no significant carry-over, P=0.4 and P=0.9, or
time effects, P=0.5 and P=0.2 for systolic or diastolic BP.
Safety results
As shown in table 3 creatinine clearance was 5% [2,8],
P=0.005 lower in the eplerenone period compared to the control
period. Mean creatinine clearance was 86 mL/min [CI: 75,97]
during control and 81 mL/min in the eplerenone period [CI:
71,93]. The time course analyses showed that, the difference was
only significant at week four of treatment versus week four of the
control period, P=0.03. There were modest increases in p-
creatinine during add-on eplerenone, although no patients had an
increase above 30%. Patients on baseline combined ACEi and
ARB tolerated eplerenone as well as the other patients.
Four patients reported increased dizziness during the treatment
period of the study compared to their usual state without any
change in BP. None required reduction in dose of eplerenone due
to dizziness alone.
No patients were withdrawn due to hyperkalaemia or other
adverse events. The mean difference in p-potassium was 0.1 mEq/
L, P,0.001 between the eplerenone and control periods, as shown
in table 3.
Four percent of all p-potassium values measured were above
5.0 mEq/L and none were above 6.0 mEq/L. Only one patient
had a single p-potassium value above 5.6 mEq/L at a planned
visit. Consequently the patient was seen at an extra control, where
p-potassium had increased to 5.8 mEq/L. Because of this, as well
as symptomatic hypotension, nausea and general discomfort the
dose of eplerenone was reduced to 25 mg daily. The patient
completed the study without further adverse effects.
There were no significant carry-over effects, P=0.3 and P=0.1,
or time effects, P=0.7 and P=0.7, for either creatinine clearance
or p-potassium.
Other parameters
Five patients had hypoalbuminemia, with a p-albumin
,3.6 g/dL. There was a significantly higher concentration of
albumin in plasma during treatment with eplerenone, P=0.004.
When the hypoalbuminemic patients were taken out of the
statistical analysis, the P-value changed to 0.006. Twenty-nine
Table 3. Results for Blood Pressure and Renal Parameters.
Eplerenone Control Treatment effect P-value
Mean [95% CI] Mean [95% CI] Mean difference [95% CI]
Systolic BP (mmHg) 121 [117,124] 124 [121,128] 24[ 26,22] 0.002
Diastolic BP (mmHg) 83 [80,86] 85 [82,88] 22[ 24,0] 0.02
P- albumin (g/dL) 4.07 [3.89,4.24] 4.00 [3.83,4.17] +0.07 [0.02,0.11] 0.004
P- bicarbonate (mEq/L) 23.9 [23.0,27.7] 24.3 [23.5,25.1] 20.4 [20.8,0.0] 0.05
P- creatinine (mg/dL) 1.56 [1.36,1.76] 1.51 [1.32,1.70] +0.06 [0.02,0.09] ,0.001
P- potassium (mEq/L) 4.4 [4.3,4.5] 4.3 [4.2,4.4] +0.1 [0.1,0.2] ,0.001
P- urea nitrogen (mg/dL) 29.97 [25.13,34.81] 26.85 [22.96,30.75] +3.11 [1.31,4.92] 0.001
Creatinine clearance
log10-values 1.91 [1.85,1.97] 1.93 [1.88,1.99] 20.02 [20.04,20.01] 0.005
(mL/min)* 81 [71,93] 86 [75,97] 25% [22,28] 0.005
Urine albumin
log10-values 3.07 [2.96,3.17] 3.17 [3.07,3.27] 20.11 [20.15,20.06] ,0.001
(mg/24hours)* 1163 [921,1468] 1481 [1192,1840] 222% [228,214] ,0.001
Fractional albumin excretion
log10-values 21.60 [21.73,21.48] 21.52 [21.63,21.40] 20.09 [20.13,20.05] ,0.001
(%)* 0.025 [0.019,0.033] 0.030 [0.023,0.033] 217% [225,211] ,0.001
Note: Conversion factors for units: creatinine in mg/dL to mmol/L, 688.4; urea nitrogen mg/dL to mmol/L, 60.357.
*Geometric mean and CI.
Percentages are obtained by subtracting log-values (treatment – control) and back-transforming by raising 10 to the difference. Values are mean values from visits at
week 1, 2, 4 and 8 in the two time periods. P-values,0.05 are considered significant.
doi:10.1371/journal.pone.0026904.t003
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treatment period, and 10 patients had lower values. Only one
of the hypoalbuminemic patients had normalization of p-
albumin in the treatment period and a 17% reduced urinary
albumin excretion in the treatment period. Four patients were
continuously hypoalbuminemic throughout the study. Two of
these patients had a reduced excretion of albumin in urine and
two had a higher excretion during treatment with eplerenone.
Along with the analysis of changes in p-albumin it was also
investigated whether there were any changes in p-cholesterol
(total), p-LDL and p-HDL cholesterol and triglycerides. Neither
of these changed significantly during the study. No patients were
started or altered in lipid lowering treatment during the study
period.
There were also no significant differences between study periods
in the following parameters: weight, BMI, p-ionized calcium, p-
uric acid, p-C-reactive-protein, blood haemoglobin, nor in the
urinary excretion of creatinine, potassium and sodium.
Figure 1. Urinary albumin excretion. Figure 1A illustrates albumin excretion during 8 weeks of add-on eplerenone as compared with control.
Figure 1B illustrates the difference in urinary albumin excretion between treatment with eplerenone and control. Data are presented as mean values
with 95% CI of the mean values. * P,0.05 for U-albumin excretion in the eplerenone period versus control period after Bonferroni correction. The
difference in U-albumin excretion at week 4 versus week 8 in the eplerenone period was not significant. Note: N=number of urine samples.
doi:10.1371/journal.pone.0026904.g001
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The present study is the first to demonstrate an antiproteinuric
effect of the selective aldosterone receptor antagonist, eplerenone,
on overt albuminuria in non-diabetic CKD. Thus, in 40 CKD
patients, add-on of eplerenone to stable antihypertensive treatment
including RAS-blockade for eight weeks caused a 22% reduced
excretion of urinary albumin compared to a control period. BP
and creatinine clearance were slightly lower during the eplerenone
period, but even after correction for that the urinary albumin
excretion was significantly lower during treatment. The validity of
the present observation rests on the randomized design of the
study. The cross-over design was chosen in order to minimize the
influence of heterogeneity between subjects and the lack of placebo
control. The absence of a carry-over effect from eplerenone to
control confirmed that no wash-out period after eplerenone was
necessary.
Reduction in albuminuria during aldosterone blockade in the
present study was less than that observed in the earlier studies.
Despite this, it is relevant to consider addition of eplerenone in
CKD patients on RAS-blockade, due to the fact that residual
proteinuria influences the prognosis for proteinuric CKD [5].
The antiproteinuric effect of eplerenone has previously only
been reported in patients with type 2 diabetes with microalbu-
minuria and in patients with essential hypertension [16,17]. A
study in type 2 diabetic patients, CKD stage 2 and microalbu-
minuria reported that add-on eplerenone to enalapril caused a
marked reduction in urine-albumin-creatinine-ratio (UACR) of
41–48% [16]. In a study of essential hypertensive patients, it was
found that 24 weeks of monotherapy with eplerenone caused a fall
in UACR of 27–28% whereas the comparator amlodipine only
caused a fall of 3–7% [17].
Studies with spironolactone have shown reduction in urinary
protein excretion in the order of 30–58% in patients with diabetic
and non-diabetic CKD stage 1–2 [11–15].
There may be two explanations for the antialbuminuric effect of
aldosterone antagonism being smaller in our study than in the
previous ones: First, in our study albuminuria was monitored in
repetitive 24 hour urine samples collected for every visit and
subsequently averaged, aiming at a high degree of accuracy of
results. By contrast, some previous studies were based on a limited
number of UACR measurements [16,17]. Second, all our patients
had overt albuminuria, while some of the patients in the earlier
studies were selected to have microalbuminuria and many had
normal renal function. Hence, our patients had a more severe
burden of renal disease than the patients in the earlier studies,
possibly restricting the effect of aldosterone antagonism on
albuminuria.
The present study was not powered to detect differences
between groups with different intensity of baseline RAS-blockade.
Patients were on stable RAS-blockade in a dose at the discretion
of their treating physician. In a post-hoc analysis we found that
the reduction in proteinuria during add-on eplerenone tended to
be most pronounced in patients treated at baseline with a
moderate level dose of RAS-blockade. In a recently published
study of diabetic patients with a UACR$300 mg/g creatinine
treatment was initially a supramaximal dose of ACEi. Spirono-
lactone or an ARB was added for 48 weeks. Reduction in UACR
was seen in both groups, but largest in the spironolactone group
[19]. A study in patients with 24 hour proteinuria .1.5 g
compared mono RAS-blockade (ACEi) to dual RAS-blockade
(ACEi+ARB or ACEi+spironolactone) and triple RAS-blockade
(ACEi+ARB+spironolactone). There was no further reduction
when spironolactone was added to dual RAS-blockade [12]. In
the present study there were a total of seven patients on dual
blockade at baseline in whom no significant decrease of albumin
excretion was seen. Of note this is at variance with other studies,
that have shown a greater reduction in urinary protein excretion
during triple RAS-blockade than during dual RAS-blockade
[12,20,21].
Interestingly, an antiproteinuric effect of eplerenone was found
in two out of the three patients with membranous nephropathy, a
disease shown in a previous prospective study to be resistant to
aldosterone inhibition [18].
As shown in figure 1A and B, there was a significant
antialbuminuric effect after two weeks of add-on eplerenone.
A short-term study of aldosterone blockade with spironolactone
in CKD has likewise shown an initial decrease in albuminuria after
just two weeks of treatment [22].
P-potassium values rose during the treatment period. Figure 2
suggests that p-potassium may reach a steady level after four weeks
of treatment with eplerenone.
The mechanisms involved in the antialbuminuric effect of
aldosterone receptor blockade have not yet been fully elucidated.
At present it is not known whether it is the classical or the non-
classical (genomic or non-genomic) effects of aldosterone that
influence progression of renal damage. An in vitro study has
shown that eplerenone blocks the non-genomic pathways of
aldosterone [23]. Other experimental studies have shown that
damage to the podocytes can be induced by aldosterone and that
this can be attenuated by eplerenone [10,24,25]. A possible
indirect mechanism of reduced protein excretion is the effect of
aldosterone on glomerular hemodynamics. Aldosterone has been
suggested to augment glomerular filtration pressure, thereby
increasing the filtration of macromolecules, a mechanism not
blocked by spironolactone [23,26,27]. One experimental study has
shown that non-genomic vasoconstriction mediated by aldoste-
rone, was blocked by eplerenone [28].
The potential risks of blocking aldosterone receptors are mainly
hypotension and hyperkalaemia. Previous studies initially reported
no major clinical problems with hyperkalaemia [11–17,29–31].
However studies reporting hyperkalaemia in the aftermath of
study participation do exist [32].
Eplerenone in contrast to spironolactone does not cause
gynecomastia or breast tenderness [33]. Gynaecomastia is in itself
a common condition in the male CKD population and has been
reported as a reason of discontinuation of treatment with
spironolactone [11,13,29].
Hence, eplerenone may be a useful drug in proteinuric patients
with CKD. The present study contributes to demonstrate
eplerenone as an alternative to treatment with spironolactone
and as a treatment alternative to patients who do not tolerate
ACE-inhibition due to side effects.
Study limitations
The group of patients studied were not homogeneous with
respect to baseline albuminuria and renal diagnoses. There were
no requirements to baseline therapy or run-in period. The study
was not designed to detect a difference in response to eplerenone
based on the baseline RAS-blocking treatment. It was an open
label design and a relatively small sample size, which limits the
extent to which results should be generalized. The statistical
analyses were based on samples from all visits which were given
equal weight in the analyses.
Conclusion
Eplerenone in a dose of 25–50 mg daily is a safe and relevant
add-on therapy in patients with non-diabetic CKD when aiming
Anti-Proteinuric Effect of Eplerenone in CKD
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e26904at a reduction in urinary albumin excretion. The potential risk
of hyperkalaemia, especially in daily practice outside the setting
of a controlled trial, should be kept in mind. Long-term studies
need to be designed in order to assess the question of whether the
effect of eplerenone on the reduction in urinary albumin
excretion is persistent, and whether the progression rate of
CKD is reduced.
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